Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment

JAMA Oncology

Volumn 1, Issue 7, 2015, Pages 943-951

  Desmond, Andrea ^a   Kurian, Allison W ^b   Gabree, Michele ^a   Mills, Meredith A ^b   Anderson, Michael J ^c   Kobayashi, Yuya ^c   Horick, Nora ^a   Yang, Shan ^c   Shannon, Kristen M ^a   Tung, Nadine ^d,e   Ford, James M ^b   Lincoln, Stephen E ^c   Ellisen, Leif W ^a,e  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Clinical Molecular Geneticist and Cytogeneticist Invitae Corportation   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; TUMOR MARKER;

BREAST TUMOR; CLINICAL TRIAL; FEMALE; GENE FREQUENCY; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HEREDITY; HUMAN; MULTICENTER STUDY; MUTATION; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PEDIGREE; PREDICTIVE VALUE; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; UNITED STATES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; BIOMARKERS, TUMOR; BOSTON; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CALIFORNIA; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEREDITY; HUMANS; MUTATION; OVARIAN NEOPLASMS; PEDIGREE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84965090778     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.2690     Document Type: Article

References (32)

1. Daly MB, Pilarski R, Axilbund JE, et al. Genetic/familial high-risk assessment: breast and ovarian, version 1.2015. J Natl Compr Canc Netw. In press.
2. Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2014;160(4): 255-266.
3. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975.
4. Finch AP, Lubinski J, Møller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547-1553.
5. Lynch HT, Snyder C, Lynch J. Hereditary breast cancer: practical pursuit for clinical translation. Ann Surg Oncol. 2012;19(6):1723-1731.
6. Stadler ZK, Schrader KA, Vijai J, Robson ME, Offit K. Cancer genomics and inherited risk. J Clin Oncol. 2014;32(7):687-698.
7. Mauer CB, Pirzadeh-Miller SM, Robinson LD, Euhus DM. The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. Genet Med. 2014;16(5):407-412.
8. Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN. Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw. 2014;12(9):1339-1346.
9. Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33(4):304-311.
10. Tung N, Battelli C, Allen B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015;121 (1):25-33.
11. Weitzel JN, Lagos VI, Cullinane CA, et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA. 2007;297(23): 2587-2595.
12. Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol. 2013;31(10):1267-1270.
13. Robson M. Multigene panel testing: planning the next generation of research studies in clinical cancer genetics. J Clin Oncol. 2014;32(19):1987-1989.
14. Njiaju UO, Olopade OI. Genetic determinants of breast cancer risk: a review of current literature and issues pertaining to clinical application. Breast J. 2012;18(5):436-442.
15. Castéra L, Krieger S, Rousselin A, et al. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet. 2014;22(11):1305-1313.
16. Kurian AW, Hare EE, Mills MA, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. 2014;32(19):2001-2009.
17. LaDuca H, Stuenkel AJ, Dolinsky JS, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2, 000 patients. Genet Med. 2014;16(11):830-837.
18. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA. 2011; 108(44):18032-18037.
19. Maxwell KN, Wubbenhorst B, D'Andrea K, et al. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Genet Med. 2014; (Dec):11.
20. Lincoln SE, Kobayashi Y, Anderson MJ, et al. A systematic comparison of traditional and multi-gene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients. J Mol Diagn. In press.
21. Bevers TB, Armstrong DK, Arun B, et al. Breast cancer risk reduction. J Natl Compr Canc Netw. 2010;8(10):1112-1146.
22. Burt RW, Cannon JA, David DS, et al; National Comprehensive Cancer Network. Colorectal cancer screening. J Natl Compr Canc Netw. 2013;11(12): 1538-1575.
23. Ahmed M, Rahman N. ATM and breast cancer susceptibility. Oncogene. 2006;25(43):5906-5911.
24. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497-506.
25. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010;42(5):410-414.
26. Osorio A, Endt D, Fernández F, et al. Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families. Hum Mol Genet. 2012;21(13): 2889-2898.
27. Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG. Increased risk of breast cancer associated with CHEK2∗1100delC. J Clin Oncol. 2007;25(1):57-63.
28. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111-1130.
29. Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42(Database issue):D980-D985.
30. Bonadona V, Bonaïti B, Olschwang S, et al; French Cancer Genetics Network. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22):2304-2310.
31. Fecteau H, Vogel KJ, Hanson K, Morrill-Cornelius S. The evolution of cancer risk assessment in the era of next generation sequencing. J Genet Couns. 2014;23(4):633-639.
32. Byrnes GB, Southey MC, Hopper JL. Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Breast Cancer Res. 2008; 10(3):208.